Quick Answer
ANAPTYSBIO, INC reported Total Assets of $364.40 million for the year ending 2025.
- ANAPTYSBIO, INC showed a decrease of -24.7% in Total Assets from 2024 to 2025.
- This data is from ANAPTYSBIO, INC's annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $131.11 million | Q2 2017: $130.41 million | Q3 2017: $121.95 million | Q1 2018: $314.84 million | Q2 2018: $306.02 million | Q3 2018: $523.12 million | Q1 2019: $494.23 million | Q2 2019: $480.15 million | Q3 2019: $451.51 million | Q1 2020: $424.23 million | Q2 2020: $401.75 million | Q3 2020: $384.75 million | Q1 2021: $396.42 million | Q2 2021: $426.57 million | Q3 2021: $424.34 million | Q1 2022: $625.17 million | Q2 2022: $603.85 million | Q3 2022: $618.50 million | Q1 2023: $551.79 million | Q2 2023: $517.10 million | Q3 2023: $487.33 million | Q1 2024: $405.84 million | Q2 2024: $427.38 million | Q3 2024: $493.42 million | Q1 2025: $422.05 million | Q2 2025: $335.25 million | Q3 2025: $353.10 million.
- Over the full 10 years of available data (2016 to 2025), ANAPTYSBIO, INC's Total Assets has grown by 486.0%.
- Historical annual values: Fiscal year 2025: $364.40 million | Fiscal year 2024: $483.83 million | Fiscal year 2023: $452.39 million | Fiscal year 2022: $610.38 million | Fiscal year 2021: $643.07 million | Fiscal year 2020: $416.55 million | Fiscal year 2019: $435.20 million | Fiscal year 2018: $509.00 million | Fiscal year 2017: $329.36 million | Fiscal year 2016: $62.18 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: